– USA, MA – Pillar Biosciences, an innovative next-generation sequencing solutions in-vitro diagnostics company, today announced the appointment of Dr. Eric Lai, Ph.D. to its Board of Directors, bringing more than 20 years of experience in drug and IVD molecular diagnostic development to the team.
“Eric brings invaluable expertise to our team at Pillar, as we work to increase access to precision medicine,” said Founder and CEO, Dr. Gang Song. “We are committed to delivering high quality, accurate, IVD testing to enable better treatment-decisions for all cancer patients.”
About Dr. Eric Lai
Dr. Eric Lai was previously SVP of Genomic Medicine at Takeda Pharmaceutical. Before Takeda, he served as SVP of Research & Development at Gen-Probe and VP, Pharmacogenetics at GlaxoSmithKline. Dr. Lai focused on clinical applications of Pharmacogenomics in drug development and safety. In 2002, he discovered the association of HLA5701 to Abacavir hypersensitivity. This discovery is frequently cited in FDA guidance as one of the most important demonstrations of precision medicine.
“I am excited to join the Board at Pillar Biosciences, to support the advancement of high-quality oncology diagnostic testing to enable precision medicine as the first option for every patient,” said Dr. Eric Lai. “Cancer testing should be provided closest to where a patient resides, and I look forward to working with the Pillar team to accelerate the development of innovative cancer diagnostics to providers and partners, and increase access to cancer testing in community centers.”
Dr. Lai received his Ph.D. in Pharmacology from Columbia University and conducted his post-doctoral training at Dr. Lee Hood’s laboratory at CalTech in the early days of the Human Genome Project. He was the co-scientific leader of The SNP Consortium and the Severe Adverse Reaction Consortium.
About Pillar Biosciences
Pillar Biosciences is a global oncology solutions company delivering in-vitro diagnostics that provide accurate, robust, timely, clinically actionable insights to guide treatment decisions throughout a patient’s continuum of care. Our mission is to enable access to high-quality, affordable, specialty NGS testing, performed by any NGS laboratory as clinical-grade tests, closer to home, for all patients. Pillar has operations in Natick, MA, and Shanghai, China.
For more information: https://pillar-biosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.